TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25234181

Group type: EXPERIMENTAL
Intervention: 7 Fr nasobiliary catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 Fr nasobiliary catheter
Number of subjects: 100
Study: 22791092

Group type: EXPERIMENTAL
Intervention: Intratracheal lucinactant (175 mg/kg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 165
Study: 20976802

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using hexylaminolevulinate (HAL) and methylaminolevulinate (MAL)
Number of subjects: 25
Study: 17359604

Group type: EXPERIMENTAL
Intervention: House dust mite impermeable bed covers and self-management plan
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo bed covers and self-management plan
Number of subjects: 126
Study: 15791112

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 100
Study: 12060470

Group type: EXPERIMENTAL
Intervention: Graphic analysis using a* and L* values from reflectance spectrometer measurements.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of adjacent normal skin for comparison.
Number of subjects: 0
Study: 9952252

Group type: EXPERIMENTAL
Intervention: Personality disordered group
Number of subjects: 39
Study: 7673693

Group type: COMPARATOR
Intervention: UVC clothing
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVC at 100 microW cm‐2 s‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVC at 300 microW cm‐2 s‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered vertical laminar flow
Number of subjects: 0
Study: 2192454

Group type: EXPERIMENTAL
Intervention: 4 x 500 mg dimethylpolysiloxane (DPS)/24 hours
Number of subjects: 13

Group type: COMPARATOR
Intervention: 2 x 500 mg dimethylpolysiloxane (DPS)/12 hours
Number of subjects: 13
Study: 402831

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound scanning
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in limbs, fluorescence and radioisotope clearance studies
Number of subjects: 3000
Study: 29746263

Group type: EXPERIMENTAL
Intervention: Uncertainty Management Program (UMP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 115
Study: 28653424

Group type: EXPERIMENTAL
Intervention: Topical application of anesthetic ointment (lidocaine/prilocaine‐AO)
Number of subjects: 444
Study: 24866348

Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 25
Study: 23246114

Group type: EXPERIMENTAL
Intervention: Satinsky clamps
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tourniquets
Number of subjects: 120
Study: 22185749

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/mL applied intraoperatively for 5 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Mitomycin C (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 30
Study: 19821717

Group type: EXPERIMENTAL
Intervention: Haishengsu (2.4 mg, intravenously for 15 days)
Number of subjects: 55
Study: 16968347

Group type: EXPERIMENTAL
Intervention: naltrexone (50 mg/day)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: acamprosate (1998 mg/day)
Number of subjects: 169

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 169
Study: 15562654

Group type: EXPERIMENTAL
Intervention: Group A: prefabricated glass‐fiber posts and Artglass polymer core
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group B: prefabricated glass‐fiber posts and Charisma composite resin core
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Group C: prefabricated glass‐fiber posts and AB composite resin core
Number of subjects: 42
Study: 11131368

Group type: EXPERIMENTAL
Intervention: Fried onions meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fried onions and fresh cherry tomatoes meal
Number of subjects: 6
Study: 9309996

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at rest
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) during exercise
Number of subjects: 9
Study: 8346819

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PHE) 2 micrograms/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Norepinephrine (NE) 0.1 microgram/kg
Number of subjects: 16
Study: 3518912

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50 Gy)
Number of subjects: 494
Study: 31740106

Group type: EXPERIMENTAL
Intervention: UP+tDCS
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: UP
Number of subjects: 43
Study: 28640990

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 37
Study: 28824764

Group type: EXPERIMENTAL
Intervention: Flipped classroom module (20-minute at-home video and 30 minutes of in-class case discussion)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard lecture (50-minute lecture from an expert educator)
Number of subjects: 73
Study: 26584035

Group type: EXPERIMENTAL
Intervention: Daclatasvir and asunaprevir
Number of subjects: 57

Group type: COMPARATOR
Intervention: Simeprevir plus PEG‐IFN/RBV
Number of subjects: 57

Group type: COMPARATOR
Intervention: Telaprevir plus PEG‐IFN/RBV
Number of subjects: 57
Study: 24127448

Group type: EXPERIMENTAL
Intervention: Vintafolide (2.5 mg IV three times per week during weeks 1 and 3) plus PLD (50 mg/m(2) IV once every 28 days)
Number of subjects: 149

Group type: COMPARATOR
Intervention: PLD alone (50 mg/m(2) IV once every 28 days)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Vintafolide plus PLD in patients with 100% of lesions positive for FR
Number of subjects: 149

Group type: COMPARATOR
Intervention: PLD alone in patients with 100% of lesions positive for FR
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Vintafolide plus PLD in patients with FR-positive disease (10% to 90%)
Number of subjects: 149

Group type: COMPARATOR
Intervention: PLD alone in patients with disease that did not express FR
Number of subjects: 149
Study: 21437915

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/dexamethasone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neomycin/polymyxin B/hydrocortisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 18182447

Group type: EXPERIMENTAL
Intervention: GH 0.8 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH 1.6 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH and DHEA (combination treatment)
Number of subjects: 16
Study: 16687344

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (LLT) after CABG (group 1, n = 102, 49% male)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group 2, n = 107, 42% male)
Number of subjects: 209
Study: 15313884

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 24535

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 24535
Study: 11024215

Group type: EXPERIMENTAL
Intervention: ACEI (Angiotensin-Converting Enzyme Inhibitor)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CCB (Calcium Channel Blocker)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9236507

Group type: EXPERIMENTAL
Intervention: Proventil HFA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ventolin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Proventil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8384096

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 50
Study: 2869346

Group type: EXPERIMENTAL
Intervention: Entamoeba histolytica excretors
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no EH excretors)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Successful eradication of EH
Number of subjects: 34
Study: 30296325

Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% (12 eyes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1% (12 eyes)
Number of subjects: 24
Study: 26412463

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (500 µg), Folic Acid (400 µg), and Vitamin D3 (600 IU) supplementation
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo with Vitamin D3 (600 IU)
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Vitamin B12 and Folic Acid supplementation
Number of subjects: 2919
Study: 24922484

Group type: EXPERIMENTAL
Intervention: CPT-C via videoteleconferencing (VTC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 125
Study: 22974472

Group type: EXPERIMENTAL
Intervention: Citicoline (2000mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20013068

Group type: EXPERIMENTAL
Intervention: Derivation cohort
Number of subjects: 10946

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 10946
Study: 19171089

Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 1 microg/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 2 microg/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 3 microg/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 4 microg/ml
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol controlled-infusion at 5 microg/ml
Number of subjects: 100
Study: 15795184

Group type: EXPERIMENTAL
Intervention: Low-dose atropine (LDA) 2 microg/kg
Number of subjects: 16
Study: 12453930

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg(‐1) followed by 250 micro g kg(‐1) min(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 50
Study: 11189685

Group type: EXPERIMENTAL
Intervention: Coordination and management processes of the PLCO trial
Number of subjects: 0
Study: 9038691

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8507448

Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with placebo (Study A)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with atenolol (50 mg orally, 12 hourly on days 1 to 10) (Study B)
Number of subjects: 6
Study: 2886541

Group type: EXPERIMENTAL
Intervention: Intra-arterial dopamine infusion after alpha-adrenoceptor blockade with phenoxybenzamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial dopamine infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine infusion after alpha-adrenoceptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulpiride (vascular dopamine receptor antagonist)
Number of subjects: 0
Study: 31714470

Group type: EXPERIMENTAL
Intervention: Fracture Liaison Service (FLS) intervention with systematic longitudinal follow-up over 2 years.
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: FLS intervention with treatment including anti-osteoporosis medication.
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: FLS intervention with monitoring of subsequent fractures.
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: FLS intervention with assessment of bone turnover markers.
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: FLS intervention with evaluation of functional capacity and pain scores.
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: FLS intervention with evaluation of quality of life scores.
Number of subjects: 532
Study: 30283014

Group type: EXPERIMENTAL
Intervention: Oral targeted therapies (ibrutinib, idelalisib, venetoclax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next-generation anti-CD20 monoclonal antibodies (obinutuzumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Programmed death 1 inhibitors (pembrolizumab, nivolumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLL-International Prognostic Index (CLL-IPI)
Number of subjects: 0
Study: 27074599

Group type: EXPERIMENTAL
Intervention: Tibialis anterior (TA) vibration on
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tibialis anterior (TA) vibration off
Number of subjects: 20
Study: 24879841

Group type: EXPERIMENTAL
Intervention: Overnight closed-loop (OCL) control
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sensor-augmented therapy (control)
Number of subjects: 20
Study: 22732281

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional percussive physiotherapy (control)
Number of subjects: 66
Study: 20580844

Group type: EXPERIMENTAL
Intervention: Memory training (8-week training regimen utilizing the Method of Loci)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 18928698

Group type: EXPERIMENTAL
Intervention: Skin to skin care and sucrose
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 54
Study: 15693728

Group type: EXPERIMENTAL
Intervention: Influenza virus vaccination
Number of subjects: 260

Group type: COMPARATOR
Intervention: Hepatitis A virus vaccination
Number of subjects: 260
Study: 12537200

Group type: EXPERIMENTAL
Intervention: Occlusive wrap dressing technique
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard longitudinal dressings
Number of subjects: 152
Study: 10380974

Group type: EXPERIMENTAL
Intervention: Ambiguous, noise‐like phoneme /f/ presented among environmental sounds (non-speech context)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambiguous, noise‐like phoneme /f/ presented among syllables (speech context)
Number of subjects: 0
Study: 8686686

Group type: EXPERIMENTAL
Intervention: Air abrasion (microetching) of previously failed bonded metal brackets
Number of subjects: 0

Group type: COMPARATOR
Intervention: New untreated brackets
Number of subjects: 0
Study: 1898694

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 385

Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 385
Study: 31856900

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate-impregnated patch
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: mupirocin ointment
Number of subjects: 354

Group type: COMPARATOR
Intervention: usual exit-site care with normal saline
Number of subjects: 354
Study: 29268756

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl
Number of subjects: 183
Study: 23857922

Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter S
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter F
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Letter fluency stimuli using the letter A
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Comparison of letter fluency performance based on university affiliation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Comparison of letter fluency performance based on sex
Number of subjects: 211
Study: 23415976

Group type: COMPARATOR
Intervention: 5 a day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: just 1 more
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 21550556

Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (PC) - paclitaxel at a dose of 140 mg/m² and carboplatin AUC3, administered on days 1 and 15
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vinorelbine/Carboplatin (VC) - vinorelbine at a dose of 45 mg/m² orally and carboplatin AUC3, administered on days 1 and 15
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (PC)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Vinorelbine/Carboplatin (VC)
Number of subjects: 153
Study: 19223527

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline (no medication)
Number of subjects: 40
Study: 17931521

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS) lobectomy
Number of subjects: 25
Study: 15028043

Group type: EXPERIMENTAL
Intervention: Mode Switching ON (MS ON)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Mode Switching OFF (MS OFF)
Number of subjects: 202
Study: 11244189

Group type: EXPERIMENTAL
Intervention: Long-slow hemodialysis (LD) for 6-8 hours at home
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard hemodialysis (SD) for 3.5-4.5 hours in the dialysis center
Number of subjects: 9
Study: 9693243

Group type: EXPERIMENTAL
Intervention: Bard BTA test
Number of subjects: 53

Group type: COMPARATOR
Intervention: Voided Urine Cytology (VUC)
Number of subjects: 53
Study: 7814344

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2503114

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 331402

Group type: EXPERIMENTAL
Intervention: Oromucosal PGE2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral PGE2
Number of subjects: 100
Study: 31918452

Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg once daily combined with EGFR-TKI
Number of subjects: 38
Study: 31188514

Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) treatment for 6 minutes
Number of subjects: 66

Group type: COMPARATOR
Intervention: Anterior Neurectomy
Number of subjects: 66
Study: 28458049

Group type: EXPERIMENTAL
Intervention: TPOL-D intervention (n=51)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Treatment-as-usual control (n=47)
Number of subjects: 98
Study: 25967124

Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine (T3) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23382493

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diet + LIRET
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LIRET
Number of subjects: 41
Study: 21212373

Group type: EXPERIMENTAL
Intervention: Hip abductor strength
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quadriceps muscle strength
Number of subjects: 31
Study: 18813917

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (5 mug) into the tibialis anterior muscle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypertonic saline injection (0.5 ml, 5.8%) into the left and right TA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline injection into the contralateral TA muscle
Number of subjects: 20
Study: 16307026

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) and chemotherapy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: High WBC counts (> or = 10,000/mm3)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: EM relapse
Number of subjects: 740

Group type: COMPARATOR
Intervention: Isolated BM relapse
Number of subjects: 740
Study: 15001403

Group type: EXPERIMENTAL
Intervention: 20 mg/kg of oral phenytoin (PO), divided in maximum doses of 400 mg every two hours
Number of subjects: 45

Group type: COMPARATOR
Intervention: 18 mg/kg of intravenous phenytoin (IVP) at an initial infusion rate of 50 mg/min
Number of subjects: 45

Group type: COMPARATOR
Intervention: 18 mg/kg of intravenous fosphenytoin (IVF) at an initial infusion rate of 150 mg/min
Number of subjects: 45

Group type: COMPARATOR
Intervention: IV groups (IVP and IVF)
Number of subjects: 45
Study: 10698387

Group type: EXPERIMENTAL
Intervention: Adenosine (250 microg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: St Thomas cardioplegic solution (Control)
Number of subjects: 60
Study: 9412257

Group type: EXPERIMENTAL
Intervention: Dopexamine at 2 micrograms/kg/min (group A, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline as control (group B, n = 10)
Number of subjects: 20
Study: 7505104

Group type: EXPERIMENTAL
Intervention: ECMV3 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 3 courses)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: ECMV6 (Etoposide, Cyclophosphamide, Methotrexate, Vincristine for 6 courses)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: EI6 (Etoposide and Ifosfamide for 6 courses)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: EI6 group
Number of subjects: 458
Study: 3805750

Group type: EXPERIMENTAL
Intervention: Lung radiotherapy (1,500 rad in 5 times with overlap on the mediastinum—3,000 rad) two weeks after surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: No lung radiotherapy
Number of subjects: 38
Study: 29601806

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 67

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 67
Study: 26541890

Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Intervention
Number of subjects: 448
Study: 24559953

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) in small tumors (≤5 cm)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group in small tumors (≤5 cm)
Number of subjects: 119
Study: 23557816

Group type: EXPERIMENTAL
Intervention: Super-tasters
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-tasters
Number of subjects: 57
Study: 20660028

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D supplementation
Number of subjects: 49

Group type: COMPARATOR
Intervention: 400 IU/d (Control)
Number of subjects: 49
Study: 17714967

Group type: EXPERIMENTAL
Intervention: GH 6 microg/kg/d (higher dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: GH 3 microg/kg/d (low dose)
Number of subjects: 16
Study: 17225547

Group type: EXPERIMENTAL
Intervention: Chinese medicine granules (1 package)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Duxil (1 tablet)
Number of subjects: 120